Production at Boehringer Ingelheim’s Ben Venue Laboratories factory in Ohio, US, was stopped in November 2011 due to product quality issues.
Ben Venue said it may resume operations by the end of 2012, the Bloomberg reported.
The New Brunswick spokeswoman Lisa Vaga was quoted by Bloomberg as saying that J&J plans to transfer the manufacturing to another supplier.
J&J plans to allow Ben Venue formulate the medication and then transfer it to another company for the filling and packaging of the product.